Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Anti-CD19 UCAR-T cells · 1 trial · 2 indications
The incidence of adverse events after CAR-T cell infusion was assessed by CTCAE, version 5.0.
The total improvement score between 0-100 also corresponds to the degree of improvement, with higher improvement scores indicating greater improvement.
Including musculoskeletal system score and skin mucosal score, with a total score of 20 points. The higher the score, the higher the disease activity
The total score is 52 points, the lower the score, the weaker the muscle strength and the more severe the disease.
| Arm | Type | Description |
|---|---|---|
| Anti-CD19 UCAR-T cells | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Anti-CD19 UCAR-T cells | DRUG | A single infusion of CD19 UCAR-T cells will be administered intravenously after lymphodepletion chemotherapy. |
Inclusion Criteria: * (1) Age ≥ 5 years old; * (2) Diagnosis of juvenile dermatomyositis (JDM) according to Bohan and Peter criteria; * (3) Meeting the classification criteria for RJDM, and meeting condition ① and any one of ② to ⑤ conditions: * Intolerance or inadequate response to glucocortico...
Anti-CD19 UCAR-T cells is an investigational cell therapy being studied for the treatment of refractory juvenile dermatomyositis (RJDM). It is designed to target CD19, a protein on B cells, and is currently in Phase 1 clinical development. The therapy is being evaluated in a clinical trial in China.
Anti-CD19 UCAR-T cells targets CD19, a cell surface protein expressed on B cells. By targeting CD19, the therapy aims to deplete B cells, which are thought to play a role in the autoimmune pathology of juvenile dermatomyositis. This mechanism is being investigated in a Phase 1 clinical trial.
Anti-CD19 UCAR-T cells is being developed by Precision BioSciences, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol DTIL. The therapy is currently in Phase 1 clinical development for refractory juvenile dermatomyositis.
Anti-CD19 UCAR-T cells is in Phase 1 clinical development. It is an investigational therapy, not yet approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to evaluate the treatment for refractory juvenile dermatomyositis.
Anti-CD19 UCAR-T cells is being studied in a Phase 1 clinical trial with the identifier NCT06686524. The trial is titled 'Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)' and is recruiting participants in China.